Addex Therapeutics (ADXN) Competitors $7.88 +0.19 (+2.52%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. ALGS, GBIO, VYNE, DARE, CLNN, TPST, GDTC, QTTB, LEXX, and CARAShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Aligos Therapeutics (ALGS), Generation Bio (GBIO), VYNE Therapeutics (VYNE), Daré Bioscience (DARE), Clene (CLNN), Tempest Therapeutics (TPST), CytoMed Therapeutics (GDTC), Q32 Bio (QTTB), Lexaria Bioscience (LEXX), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Aligos Therapeutics Generation Bio VYNE Therapeutics Daré Bioscience Clene Tempest Therapeutics CytoMed Therapeutics Q32 Bio Lexaria Bioscience Cara Therapeutics Aligos Therapeutics (NASDAQ:ALGS) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings. Does the media favor ALGS or ADXN? In the previous week, Addex Therapeutics had 7 more articles in the media than Aligos Therapeutics. MarketBeat recorded 9 mentions for Addex Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.94 beat Addex Therapeutics' score of 0.63 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Addex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ALGS or ADXN? Aligos Therapeutics has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Do analysts rate ALGS or ADXN? Aligos Therapeutics currently has a consensus target price of $70.00, suggesting a potential upside of 1,085.44%. Addex Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 280.52%. Given Aligos Therapeutics' higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in ALGS or ADXN? Aligos Therapeutics received 14 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Aligos Therapeutics an outperform vote while only 51.72% of users gave Addex Therapeutics an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% Addex TherapeuticsOutperform Votes1551.72% Underperform Votes1448.28% Is ALGS or ADXN more profitable? Addex Therapeutics has a net margin of 850.30% compared to Aligos Therapeutics' net margin of -1,283.19%. Addex Therapeutics' return on equity of -112.43% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% Addex Therapeutics 850.30%-112.43%-77.95% Which has better earnings and valuation, ALGS or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$3.95M9.15-$87.68M-$20.90-0.28Addex Therapeutics$556.05K15.03-$11.76M-$0.34-23.19 Do insiders and institutionals have more ownership in ALGS or ADXN? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAligos Therapeutics beats Addex Therapeutics on 9 of the 16 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.36M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-23.197.3622.6118.58Price / Sales15.03241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book6.576.486.704.26Net Income-$11.76M$143.43M$3.22B$248.31M7 Day Performance5.04%1.69%1.26%1.34%1 Month Performance6.61%6.58%3.73%3.92%1 Year Performance-2.79%-2.63%15.82%5.33% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.3781 of 5 stars$7.88+2.5%$30.00+280.5%+1.8%$8.36M$556,045.00-23.1930Short Interest ↓News CoverageGap UpALGSAligos Therapeutics3.8955 of 5 stars$4.62-1.3%$70.00+1,415.2%-70.8%$28.25M$3.95M-0.3590Upcoming EarningsGap UpGBIOGeneration Bio3.5871 of 5 stars$0.42+6.4%$7.33+1,658.6%-84.7%$27.94M$19.89M-0.19150Positive NewsHigh Trading VolumeVYNEVYNE Therapeutics2.4763 of 5 stars$1.79-3.2%$6.88+284.1%-47.2%$27.23M$501,000.00-2.0830Upcoming EarningsShort Interest ↑DAREDaré Bioscience2.2856 of 5 stars$2.97+2.4%$24.00+708.1%-20.1%$26.28M$9,784.00-5.0330Short Interest ↓CLNNClene2.8295 of 5 stars$3.02+0.7%$55.25+1,729.5%-65.6%$25.96M$342,000.00-0.57100Upcoming EarningsTPSTTempest Therapeutics2.0125 of 5 stars$7.11-2.3%$30.00+321.9%-84.2%$25.02MN/A-4.6520Upcoming EarningsGDTCCytoMed Therapeutics2.1502 of 5 stars$2.28-7.3%$5.00+119.3%+12.3%$24.94MN/A0.00N/AGap DownQTTBQ32 Bio2.6728 of 5 stars$2.03-4.2%$24.71+1,117.5%-94.2%$24.76M$-6,651,000.00-0.1439Upcoming EarningsShort Interest ↓News CoverageLEXXLexaria Bioscience2.426 of 5 stars$1.39+0.7%$7.00+403.6%-62.5%$24.41M$525,923.00-2.787Short Interest ↓Analyst RevisionCARACara Therapeutics3.8767 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies Aligos Therapeutics Alternatives Generation Bio Alternatives VYNE Therapeutics Alternatives Daré Bioscience Alternatives Clene Alternatives Tempest Therapeutics Alternatives CytoMed Therapeutics Alternatives Q32 Bio Alternatives Lexaria Bioscience Alternatives Cara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADXN Stock Free ADXN Stock Alerts